TABLE 2.

Drug Treatment, HIV Testing and Treatment, and Harm Reduction Services in Sub-Sahara Africa, Middle East/North Africa, Australia, India, Indonesia, and Thailand Among WWID^*

Country	PWID Who Are Women (%)	HIV Prevalence Among WWID (%)	OAT	VCT	ART	NSEP
Pakistan	1.6	6	P	LC	LC	Y
Iran	6	8.7	Y	Y	Y	Y
Afghanistan	NR	3.7	E	Y	Y	Y
Australia	33†	0.8‡	Y	Y	Y	Y
South Africa	27	19.4	Y	Y	Y	Y
Kenya	11	18–44	E	LC	Y	LC
Tanzania	NR	72	E	Y	Y	LC
Nigeria	NR	<10§	E	LC	Y	LC
India	NR	13∥	Y	Y	Y	Y
Indonesia	11	57.1¶	LC	LC	LC	LC
Thailand	NR	29.7∥	LC	LC	LC	LC

^*Data from this table with the exception of the specific references given were either provided in the text of the manuscript or based on knowledge of the specific country where authors of this manuscript have conducted research.

Data sources:

^†Degenhardt L, Whiteford H, Ferrari A, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. The Lancet. 2013;382:1564–1574.

^‡Australian Needle and Syringe Program National Data Report 2009–2013. The Kirby Institute, University of New South Wales; 2014. https://kirby.unsw.edu.au/sites/default/files/hiv/resources/ANSPS-NDR-2009-2013-2.pdf

^§Eluwa GI, Strathdee SA, Adebayo SB, Ahonsi B, Adebajo SB. A profile on HIV prevalence and risk behaviors among injecting drug users in Nigeria: should we be alarmed? Drug Alcohol Depend. 2013;127:65–71.

^∥UNAIDS, 2012.

^¶UNAIDS, 2009.

E, emerging; LC, low coverage; NR, not reported; OAT, opioid agonist treatment; P, pilot data only; VCT, volunteer HIV counseling and testing; Y, yes.